{"filings":[{"id":2105846,"accession_number":"0001193125-26-337964","cik":2044725,"company_name":"Evommune, Inc.","ticker":"EVMN","form_type":"8-K","filed_at":"2026-08-06T20:06:15+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evommune Q2 net loss $32.2M; EVO756 AD Phase 2b data due Sept 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $32.2M for Q2 2026 vs $13.6M in Q2 2025; cash $288M as of June 30, 2026.","EVO756 Phase 2b top-line data in moderate-to-severe atopic dermatitis expected September 2026.","EVO756 migraine prophylaxis Phase 2b trial initiated; top-line data anticipated in 2027.","Discontinued EVO756 development in chronic spontaneous urticaria after Phase 2b missed primary endpoint.","EVO301 Phase 2a full positive data set in AD to be presented at upcoming medical conference; Phase 2b to start mid-2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":826441541.1358184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1950321,"accession_number":"0001193125-26-324972","cik":2044725,"company_name":"Evommune, Inc.","ticker":"EVMN","form_type":"8-K","filed_at":"2026-07-30T12:01:01+00:00","items":["7.01","9.01"],"status":"ready","headline":"Evommune doses first patient in Phase 2b trial of EVO756 for migraine prophylaxis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in Phase 2b trial of MRGPRX2 inhibitor EVO756 for migraine prophylaxis.","Global, randomized, double-blind, placebo-controlled, dose-ranging trial with ~330 patients over 12 weeks.","Top-line data expected in 2027; daily doses up to 100 mg being tested.","EVO756 designed to inhibit three key neuropeptides (PACAP, VIP, Substance P) via MRGPRX2.","Primary endpoint: mean change from baseline in monthly migraine days (MMD)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":826441541.1358184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1315836,"accession_number":"0001193125-26-286918","cik":2044725,"company_name":"Evommune, Inc.","ticker":"EVMN","form_type":"8-K","filed_at":"2026-06-29T12:32:15+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Evommune EVO756 Phase 2b misses primary endpoint in CSU; development halted for that indication","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2b trial of EVO756 in 160 CSU patients did not meet primary endpoint of UAS7 change at 12 weeks at any dose.","Company will cease EVO756 development for CSU but will continue evaluation in atopic dermatitis and migraine.","Top-line Phase 2b data for EVO756 in atopic dermatitis expected Q3 2026; migraine trial screening initiated.","Cash position supports anticipated operations through 2028; EVO301 Phase 2b for AD in planning."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":826441541.1358184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":805876,"accession_number":"0001193125-26-253482","cik":2044725,"company_name":"Evommune, Inc.","ticker":"EVMN","form_type":"8-K","filed_at":"2026-06-02T20:07:07+00:00","items":["5.07"],"status":"ready","headline":"Evommune stockholders elect Peña and Bauer as directors, ratify BDO auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Luis Peña elected with 21,859,596 votes for, 1,949,148 withheld, and 885,750 broker non-votes.","Eugene Bauer elected with 23,637,920 for, 170,824 withheld, and 885,750 broker non-votes.","Ratification of BDO USA as auditor approved: 24,664,299 for, 430 against, 29,765 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":826441541.1358184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97456,"accession_number":"0001193125-26-211934","cik":2044725,"company_name":"Evommune, Inc.","ticker":"EVMN","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Evommune reports Q1 net loss $21.7M; EVO756 Phase 2b data due June 2026 in CSU","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.7M in Q1 2026 vs $14.6M prior year; cash, equivalents and investments $307.0M as of March 31, 2026.","EVO756 Phase 2b top-line data in chronic spontaneous urticaria expected June 2026; atopic dermatitis data in Q3 2026.","Phase 2b dose-ranging trial for EVO756 in migraine prophylaxis to start mid-2026; top-line data anticipated in 2027.","EVO301 Phase 2b atopic dermatitis trial planned for mid-2027 after positive Phase 2a proof-of-concept data in February 2026.","Revenue zero vs $3.0M prior year (Maruho collaboration ended); R&D expenses $17.3M, G&A $6.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":826441541.1358184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97455,"accession_number":"0001193125-26-152864","cik":2044725,"company_name":"Evommune, Inc.","ticker":"EVMN","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Evommune hosts webcast on MRGPRX2 inhibition for migraine treatment","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation reviews migraine treatment landscape and potential role of MRGPRX2 inhibition.","No new clinical data, financial results, or regulatory milestones disclosed.","Webcast replay available on company IR website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":826441541.1358184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112258,"accession_number":"0001193125-26-093920","cik":2044725,"company_name":"Evommune, Inc.","ticker":"EVMN","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Evommune reports Q4/FY2025 net loss $28.3M/$68.9M; positive EVO301 Ph2a data; $125M raise","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $28.3M; FY net loss $68.9M vs $66.8M prior year. Revenue $13.0M FY (Maruho deal). Cash $216.7M at Dec 31, 2025.","Positive Phase 2a POC data for EVO301 in atopic dermatitis: met primary endpoint, 33% placebo-adjusted EASI reduction at week 12 after 2 doses.","EVO756 Phase 2b top-line data expected 2Q26 for CSU, 2H26 for AD; Phase 2b in migraine to start mid-2026.","Closed $125M private placement in Feb 2026; cash runway extended through 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":826441541.1358184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112257,"accession_number":"0001193125-26-049888","cik":2044725,"company_name":"Evommune, Inc.","ticker":"EVMN","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Evommune announces $125M private placement of 4.5M shares at $27.88/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$125M from sale of 4,494,279 shares at $27.88 per share to institutional investors.","Investors include new and existing mutual funds and dedicated healthcare funds.","Net proceeds to advance clinical development programs and for general corporate purposes.","Transaction expected to close on or about February 17, 2026, subject to customary conditions.","Registration rights agreement filed; resale registration statement to be filed within 60 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":826441541.1358184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112256,"accession_number":"0001193125-26-043771","cik":2044725,"company_name":"Evommune, Inc.","ticker":"EVMN","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Evommune reports positive Phase 2a top-line data for EVO301 in atopic dermatitis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: 99.8% of posterior distribution exceeded 8% improvement threshold vs placebo.","Frequentist analysis showed p<0.01 at weeks 4, 8, 12; 33% placebo-adjusted EASI reduction at week 12.","23% of EVO301 patients achieved vIGA-AD 0/1 at week 12 vs 0% placebo.","EVO301 well tolerated; no related serious/severe AEs or treatment discontinuations.","Company plans Phase 2b dose-ranging trial with subcutaneous formulation; evaluating ulcerative colitis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":826441541.1358184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128841,"accession_number":"0001193125-25-315918","cik":2044725,"company_name":"Evommune, Inc.","ticker":"EVMN","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evommune reports Q3 2025 net loss $12.5M; IPO raised $172.5M, three Phase 2 readouts due in 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Completed IPO in Nov 2025 of 10.78M shares at $16.00, raising $172.5M gross proceeds.","Three Phase 2 data readouts expected in 2026: EVO756 CSU (1H26), EVO756 AD (2H26), EVO301 AD (1H26).","Q3 2025 revenue $10.0M from Maruho collaboration; zero in prior-year quarter.","Net loss improved to $12.5M vs $15.9M YoY; cash and investments $76.0M as of Sep 30, 2025.","R&D expenses increased to $19.6M from $13.3M YoY, reflecting pipeline advancement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":826441541.1358184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128840,"accession_number":"0001193125-25-272282","cik":2044725,"company_name":"Evommune, Inc.","ticker":"EVMN","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Evommune amends charter and bylaws upon IPO closing on Nov 7, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed amended and restated certificate of incorporation with Delaware Secretary of State on November 7, 2025.","Adopted amended and restated bylaws effective immediately prior to IPO closing, as pre-approved by board and stockholders.","IPO closed on November 7, 2025; amendments are standard governance updates for a public company.","Company is an emerging growth company trading on NYSE under symbol EVMN."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":826441541.1358184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}